the classification dossier.

Before preparing your classification dossier, assess whether your product constitutes an ATMP based on the criteria set forth in the European Union (EU) Regulation No 1394/2007. This regulation emphasizes several key points for ATMP classification:

• Products must be derived from human cells or tissues.
• The primary mode of action should be related to the modification of biological systems, whether by the introduction of genes or cells.
• The product must provide a therapeutic, preventive, or diagnostic benefit.

Understanding these classifications is crucial for determining how to organize your dossier and which regulatory pathways will be applicable. For products that fall at the intersection of medicinal products and medical devices, or those that involve combined ATMPs, consult the relevant guidelines to ensure compliance with requirements for borderline products.

Step 2: Conducting Pre-Dossier Preparation Meetings

Once you have determined your ATMP’s classification, conduct meetings with your development team and possibly the EMA. Pre-dossier preparation meetings are critical for aligning on strategy and understanding data expectations. These discussions will help tailor your evidence-gathering to meet EMA expectations effectively.

When engaging with the EMA, consider the following:

• Submit a detailed briefing document outlining your product, its intended use, and preliminary data. Engagement with regulatory authorities early in the development process is invaluable.
• Establish the need for a formal scientific advice procedure if necessary, which can help clarify the EMA’s expectations regarding the types of data required.
• Document the outcomes of the meeting and follow up with the EMA to ensure that you have interpreted the advice correctly.

The feedback received during these pre-dossier meetings will inform the data and documentation needed for the classification dossier. This ensures your submission is aligned with EMA guidance as you move forward.

Step 3: Compiling the Classification Dossier

With an understanding of your ATMP’s classification and a clear direction from the EMA, it is time to compile the classification dossier. The dossier must be comprehensive, organized, and include all necessary evidence supporting your product’s classification. The EMA provides detailed guidance on the structure and content of the dossier, found in the [Guidelines on ATMPs](https://www.ema.europa.eu/en). The dossier should generally include:

• Administrative Information: This should include product name, name of manufacturer(s), and the person responsible for the product.
• Quality Data: Comprehensive quality data is crucial, including descriptions of the production process, quality control measures, and stability data.
• Safety Data: Provide safety information supporting the use of the ATMP, including preclinical and clinical data.
• Efficacy Data: Detail how the product effectively achieves its intended therapeutic benefit.
• Risk Management Plan: Include risk mitigation strategies relevant to the product.

Ensure that each section is detailed yet concise. The primary goal is to demonstrate compliance with EMA regulations. Include relevant studies, preclinical data, and clinical trial results. Remember that completeness of documentation is vital, as any missing information can lead to delays in classification or a negative assessment.

Step 4: Formatting and Submission of the Dossier

Once you compile the necessary sections of the classification dossier, it must be formatted according to EMA guidelines before submission. This entails adhering to specific formatting requirements for electronic submissions, such as using the Common Technical Document (CTD) format. The CTD format facilitates regulatory information management and is the standard for regulatory submissions in the EU.

Key considerations for formatting and submission include:

• Electronic Common Technical Document (eCTD): Ensure the dossier is prepared in an eCTD format if submitting via the eSubmission portal.
• Content and Structure: Maintain clear headings, tables, and figures, ensuring data is easily accessible and interpretable.
• Submission Logistics: Utilize the EMA’s online submission platform, ensuring all required documentation is uploaded correctly.

After submission, set up a tracking process to monitor your dossier’s status within the EMA’s review system. An organized tracking process ensures timely follow-up and response to any queries from the EMA.

Step 5: Engaging in the Review Process

After submission, the dossier enters the review process, which is critical for classification. The review is conducted by the EMA’s CAT, which will assess the application based on scientific criteria, safety, and efficacy of the product as an ATMP. During this phase, it is essential to remain responsive and prepared for possible questions or requests for additional information from the agency.

Consider the following points during the review process:

• Timeliness of Responses: Respond promptly to any requests from the EMA for clarification or additional data.
• Continual Communication: Maintain an open line of communication with the reviewers to facilitate a smooth review process.
• Review Meetings: Be open to participating in meetings with the EMA to discuss the dossier and respond to queries effectively.

The review process aims to achieve a thorough evaluation to grant classification as an ATMP. Any deficiencies identified must be addressed swiftly to prevent extended delays in the classification decision.

Step 6: Receiving the Classification Decision and Next Steps

Upon completion of the review, the EMA will issue a classification opinion. Depending on the assessment results, the opinion may indicate clear classification as an ATMP, or it can request further information or clarification. If classified as an ATMP, you are now positioned to move forward with the next phases of development and potentially market authorization.

Position the following next steps based on the EMA’s decision:

• Commencement of Clinical Trials: If classification is granted, you may start planning for the clinical trial application (CTA) and associated studies.
• Preparation for Market Authorization: Begin assembling your marketing authorization application (MAA) dossier, incorporating data from your classification dossier.
• Ongoing Communication with EMA: Continue to engage with the EMA for any changes, updates, or additional submissions as required throughout the development process.

Regardless of the classification outcome, maintain alignment with EMA guidelines as continued diligence is essential in regulatory compliance.

Step 7: Post-Approval Commitments and Monitoring

Following successful classification and advancement through clinical development, you must implement post-approval commitments and monitoring to ensure compliance with regulations. The EMA may impose specific conditions or require ongoing commitments to monitoring adverse events, conducting additional studies, or implementing post-marketing surveillance.

Essential practices post-approval include:

• Risk Management: Activate the risk management framework established during the classification process, aligning with EU pharmacovigilance requirements.
• Regular Reporting: Submit regular safety and efficacy updates according to the EMA’s requirements.
• Continuous Documentation: Maintain comprehensive records of all activities, communications, and investigations related to the ATMP.

Through diligent monitoring and adherence to regulatory requirements, organizations can facilitate ongoing compliance and assurance of product safety and efficacy. This ongoing collaboration and communication with the regulatory authorities ensures a product remains safe for the patient population it aims to benefit.

In conclusion, preparation of an EMA CAT classification dossier is a step-by-step process that requires thorough planning, documentation, and engagement with regulatory authorities. By understanding ATMP classification, compiling clear and concise evidence, and proactively managing the submission and review process, regulatory professionals can enhance their chances of successful classification and subsequent market entry.